Susan Ashwell

This inventor holds 50 USPTO granted patents and 15 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Mutant IDH Inhibitors. Top assignees: Forma Therapeutics, Inc., Elan Pharmaceuticals, Inc., Wyeth. Active years: 2001-2025.

USPTO Granted Patents = 50 (Patent Applications = 15)

% Patents Active = 46.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 9.3

ph-index = 15

Forward Citations = 473(Granted Patents)

Forward Citations (Not Self Cited) = 231(Dec 10, 2025)

Location History:

Lexington, MA (US) (2004 - 2007)
Plainsboro, NJ (US) (2001 - 2011)
Carlisle, MA (US) (2017 - 2024)

Company Filing History:

23 out of 125

Forma Therapeutics, Inc.

patents

12 out of 202

Elan Pharmaceuticals, Inc.

5. 10 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Mutant Isocitrate Dehydrogenase

Quinolinone Derivatives

Leukocyte Adhesion

VLA-4 Inhibitors

Alpha Amino Acids

Beta Amino Acids

Heterocyclic Compounds

Pyridin-2(1H)-one

Fused-Bicyclic Aryl

Phenylalanine Derivatives

Heteroaryl Compounds

Carbamyloxy Compounds

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

2. 11963956 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2024-04-23),

3. 11738018 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2023-08-29),

4. 11576906 - Inhibiting mutant IDH-1 (2023-02-14),

5. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

6. 11497743 - Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation (2022-11-15),

7. 11376246 - Inhibiting mutant IDH-1 (2022-07-05),

8. 11311527 - Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) (2022-04-26),

9. 11013734 - Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation (2021-05-25),

10. 11013733 - Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) (2021-05-25),

11. 10889567 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2021-01-12),

12. 10807976 - Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors (2020-10-20),

13. 10577329 - Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2020-03-03),

14. 10550099 - Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors (2020-02-04),

15. 10550098 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2020-02-04),

Title: The Innovative Mind of Susan Ashwell: A Pioneering Inventor in Cancer Treatment

Introduction: Susan Ashwell, based in Carlisle, MA, is a distinguished inventor with an impressive portfolio of 26 patents. Her groundbreaking work primarily focuses on innovative therapeutic compositions aimed at treating cancers associated with specific genetic mutations. Susan's contributions to the field of oncology exemplify the impact of targeted therapies and highlight her role as a leading figure in pharmaceutical innovation.

Latest Patents: Among her latest patents, Susan’s notable work includes a method for Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1). This invention presents a significant advancement for patients diagnosed with cancers harboring an IDH-1 mutation. Her pharmaceutical composition encompasses Compound 1, a selective inhibitor that effectively reduces the production of 2-HG from mIDH-1 enzymes. This groundbreaking patent also addresses various R132 mutations, such as R132C, R132H, R132L, R132G, and R132S, which are critical targets in her therapeutic approach.

Career Highlights: Susan's illustrious career includes significant roles at Forma Therapeutics, Inc. and Forma Tm2, Inc. Throughout her professional journey, she has been at the forefront of research and development, driving innovations that pave the way for new treatment modalities in cancer therapy. Her extensive patent portfolio reflects her commitment to addressing complex medical challenges through inventive solutions.

Collaborations: Susan has collaborated with esteemed colleagues in her field, including Wei Lu and Jian Lin. These partnerships have fostered a collaborative environment that enhances research capabilities and accelerates the development of novel therapeutic strategies.

Conclusion: Susan Ashwell's innovative spirit and dedication to advancing cancer treatment through targeted therapies solidify her status as a leading inventor. With her extensive patent portfolio and collaborative work within the pharmaceutical industry, she continues to inspire future generations of scientists and researchers committed to making a difference in the fight against cancer.